Entrada Therapeutics Q2 net loss narrows on lower costs
TRDA•Outlook
- Company believes cash position will fund operations into Q3 2027
Overview
- Biopharmaceutical firm's Q2 net loss narrowed
- Q2 collaboration revenue fell year-over-year
Key Details
| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|---|---|---|
| Q2 Net Loss | $42.76 mln | ||
| Q2 Income From Operations | -$44.96 mln | ||
| Q2 Operating Expenses | $45.86 mln |
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell". The average consensus recommendation for the biotechnology & medical research peer group is "buy". Wall Street's median 12-month price target for Entrada Therapeutics, Inc. is $20.00, about 176.2% above its August 4 closing price of $7.24.
Result Drivers
- Collaboration revenue decline - Co said Q2 collaboration revenue fell mainly due to lower contributions from partnerships
- Lower R&D costs - Co attributed decreased R&D expenses to lower personnel and facility costs, partially offset by higher DMD program expenses
